1Liu B, Beral V, BaIkwill A, et al. Gallbladder disease and use of trans- dermal versus oral hormone replacement therapy in postmenopausal women : prospective cohort study[ J]. BMJ,2008,337 : A386.
2Mcnon DV, Vongpatanasin W. Effects of transdermal estrogen replace- ment therapy on cardiovascular risk factors [ J ]. Treat Endocrinol, 2006,5(1) :37 -51.
2Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration [ J ]. Climacteric, 2005,8 ( 1 ) : 3 -63.
3Liu B, Beral V, Balkwill A, et al. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study[J]. BMJ, 2008,337(7656) : 386 - 389.
4Canonico M, Plu-Bureau G, Lowe GD, et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women : systematic review and meta-analysis [ J ]. BMJ, 2008,336 (7655) : 1227 - 1231.
5Dupont A, Dupont P, Cusan L, et al. Comparative endocrinological and clinical effects of pereutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women[ J]. Maturitas, 1991,13 (4) :297 -311.
6Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and ve- nous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens : the ESTHER study [J]. Circulation, 2007,115(7) :840-845.
7Beral V. Breast cancer and hormone-replacement therapy in the Mil- lion Women Study[J]. Lancet, 2003,362(9382) :419 -427.
8Espie M, Mares P, de Reilhac P, et al. Breast cancer in postmenopausal women with and without hormone replacement therapy: preliminary results of the MISSION study [ J ]. Gynecol Endocrinol, 2006,22(8) :423 -431.
9Isoniemi H, Appelberg J, Nilsson CG, et al. Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteopo- rosis a 2-year follow-up study [ J ]. J Hepatol, 2001,34 ( 2 ) : 299 - 305.
